Medicine Overview of Erlocip
Erlocip 150mg which belongs to a type of classification of tyrosine kinase inhibitor, which prevent the growth of cancer cells and reduce the spreadness in the body. Erlocip 150mg tablet indicated for non-small cell lung cancer or pancreatic cancer which spread to all over the body. Erlocip 150mg recommended after other chemotherapy drug used without given any success. Erlocip is a prescription drug, without prescription should not be issued.
Uses of Erlocip
Erlocip 150mg mainly prescribed for non- small lung cancer and pancreatic cancer.
Non-small lung cancer: Erlocip preferred has first line therapy in patient with NSCLC in which there disease have no progressed after 4cycles of platinum-based first line chemotherapy.
Pancreatic cancer: Erlocip used with combination of gemcitabine for the first line therapy in patient with advance metastatic pancreatic cancer.
Side effects of Erlocip
Erlocip 150mg major side effects:
Vomiting and nausea
Loss of appetite
Contact a doctor immediately encounters more severe side effects such as:
Yellow colour in skin or eyes
Signs of infection
Black, bloody or tarry stools and dark urine
Eye irritation or pain
Vision or speech problems
Shortness of breath
How to use Erlocip
Erlocip is administer in tablet form to be consume by mouth at least one hour before or two hours after eating. The tablets are supplied in 25mg, 100mg and 150mg strengths.
Non-small cell lung cancer: Analysing of EGFR mutation testing before Erlocip treatment. Dose prescribed 150mg one tablet taken 1hour or 2 hour after the meal.
Pancreatic cancer: Erlocip dose of 100mg combination with gemcitabine ( 1hr or 2hr after the meal). Requirement of dose adjustment to reduce in 50mg steps.
Erlocip tablet used on an empty stomach 1hr before or 2hr after the digestion of food. Swallow the tablet via orally. Avoid concomitant use of proton pump inhibitor with Erlocip tablet.
Hepatic impairment: Based on severe adverse reaction occurs the dose reduction of Erlocip is studied in patient with severe hepatic impairment.
Erlocip exposure will be reduced in cigarette smoking patient
If any gastric problem with Erlocip then take it 10 hrs after H2 receptor or before 2hrs of next antacid dose
Safety and efficacy has not established in renal impairment, pregnancy use.
In pediatric: Safety and efficacy is not established <18years.
IF OVERDOSAGE OCCURS: Erlocip with overdose the symptoms of diarrhea, rash and liver transminase elevation occurs then urgent symptomatic and supportive treatment required.
How to Erlocip works
In the body, certain cells grow and multiply in a way that is 'out of control' means cancer. Erlocip interfere with the cells grow and increase in number. Erlocip works by preventing certain enzymes called tyrosine kinases that are needed for the transmitting the chemical signals which is require for essential processes like cell division and replication in cancer cells. Which in turn Erlocip blocks the cancer cells from growing and increasing in number.
ABSORPTION: Erlocip 60% absorbed and bioavailability is subsequently increased by food (100%). Peak plasma level about 4 hours after dosing.
DISTRIBUTION: Erlocip bounded to plasma albumin protein and alpha-1acid glycoprotein is approximately 93%.
METABOLISM: Erlocip 150 mg tablet mainly metabolized by CYP3A4 and to a lesser action by CYP1A2, and the extrahepatic isoform CYP1A1. Steady state plasma concentration of Erlocip is about 7-8 days.
EXCRETION: Erlocip eliminated in feces 83% and 8% in urine and half life of 36.2 hours.91% is recovered dose.
In Depth Information on Erlocip
Expert Advice for Erlocip
- If you are allgeric to the Erlocip or any other medicine, immediately inform your doctor.
- While taking Erlocip,Inform your doctor about previously taking medicine involved in prescription and non prescription, over the counter, vitamins, herbal, nutritional supplements.
- Antacid should consume several hours before and after the drug Erlocip.
- On treatment of Erlocip, avoid becoming pregnant for a month after final dose. Consult with doctor because Erlocip may affect the fetus.
- Due to use Erlocip, skin problem occurs for protection use mild alcohol free moisturizer.
On Erlocip treatment avoid grapefruit or grapefruit juice
Special Warnings of Erlocip
While taking Erlocip150mg, alcohol interaction is unknown. Please consult with doctor.
Based on side effects there is positive evidence of human fetal risk In pregnant women use of Erlocip 150mg may be gain acceptable against the risk means if the drug is used in a life-threatening situation are ineffective.
On treatment with Erlocip 150mg, breastfeeding is not recommended because unknown reason in animal milk and affects the nursing infants.
Erlocip 150mg tablet alters the ability to drive is unknown. If you experience any symptoms that affect your ability to concentrate then avoid driving unless you feeling well
Erlocip 150mg tablet is safe to use with kidney problem patients. No dose adjustment is required. In severe kidney disease patient’s use of Erlocip is not advisable.
No dosage adjustment required in patients with baseline mild liver disease. Avoid using of Erlocip 150mg while patients with baseline severe hepatic impairment . Dose adjustment may be required. Please consult with your doctor.
The drug dose is missed, then take the drug dose as soon as possible. If next dose time arrived then skip the missed dose and continue the routine schedule. Avoid taking extra dose or 2 dose at one time. Please consult your doctor for further clarification
Amazing Review by Millionpharma
Write Your Own Review
Category: --------------------Anti-Cancer Drugs
Sub Category:-------------------- Erlotinib
Brand name:-------------------- Erlocip
Ingeridents(Generic Name) :-------------------- Erlotinib
Package:-------------------- 30 TABLETS/1X30
Strength :-------------------- 150mg